10-Q: CV Sciences Reports Q3 Loss, Faces New THC Regulations

CV Sciences, Inc. reported a reduced net loss for Q3 and the first nine months of 2025, but faces significant challenges from new federal THC regulations and ongoing liquidity concerns.

Summary

• Net loss for the three months ended September 30, 2025, improved to $(382) thousand from $(456) thousand in the prior year period.
• Net loss for the nine months ended September 30, 2025, significantly improved to $(752) thousand from $(1,668) thousand in the prior year period.
• Product sales decreased by 15.8% to $3.256 million in Q3 2025 and by 11.3% to $10.482 million for the nine months ended September 30, 2025, primarily due to lower sales volume from out-of-stock issues and restrictive state regulations.
• Gross margin improved to 48.5% in Q3 2025 (from 46.0% in Q3 2024) and for the nine months (from 46.5% in 2024) due to lower freight, inventory losses, and product/channel mix.
• Cash flows used in operating activities significantly improved to $(53) thousand for the nine months ended September 30, 2025, compared to $(697) thousand in the prior year.
• The company derecognized a $0.5 million contingent liability for employer and employee Medicare FICA taxes due to the expiration of the statute of limitations on April 15, 2025.
• As of September 30, 2025, cash stood at $381 thousand and working capital at $311 thousand.
• A new federal law, effective November 13, 2026, will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container, which could materially impact the company.
• The company secured $300,000 in net proceeds from a new secured promissory note in October 2025.

Sentiment

Score: 3

Explanation: While the company showed some improvement in net loss and operating cash flow, significant concerns remain regarding declining sales, ongoing liquidity issues, and the 'going concern' warning. The new federal THC regulations pose a substantial future threat to the core business, and manufacturing constraints add near-term operational challenges. The recent capital raise provides limited short-term relief but doesn't fully address the underlying financial fragility and regulatory headwinds.

Positives

• Net loss significantly reduced for both the three and nine months ended September 30, 2025, compared to the prior year periods.
• Gross margin improved to 48.5% for both the three and nine months ended September 30, 2025, driven by lower freight, inventory losses, and product/channel mix.
• Cash flows used in operating activities improved substantially, from $(697) thousand in 9M 2024 to $(53) thousand in 9M 2025.
• Working capital increased to $311 thousand as of September 30, 2025, from $134 thousand as of December 31, 2024.
• Derecognized a $0.5 million contingent liability for payroll taxes due to statute of limitations expiration, positively impacting the income statement.
• Successfully repaid the Streeterville Note prior to maturity, recognizing a $37,500 gain on extinguishment.
• Secured $300,000 in net proceeds from a new promissory note in October 2025, providing additional liquidity.

Negatives

• Product sales decreased by 15.8% in Q3 2025 and 11.3% for the nine months ended September 30, 2025, primarily due to lower sales volume, out-of-stock issues, and restrictive state regulations.
• The company's financial operating results and accumulated deficit of $87.7 million raise substantial doubt about its ability to continue as a going concern.
• Adjusted EBITDA for Q3 2025 worsened to $(118) thousand from $(75) thousand in Q3 2024.
• Cash balance decreased to $381 thousand as of September 30, 2025, from $454 thousand at December 31, 2024.
• The acquisition of Extract Labs was purportedly terminated by the sellers, which the company disputes and is evaluating options.
• Manufacturing constraints are expected to cause temporary out-of-stock situations for key products in Q4 2025 and early 2026.

Risks

• Going Concern Uncertainty: The company's negative cash flows from operations ($0.1 million for 9M 2025) and accumulated deficit ($87.7 million as of Sep 30, 2025) raise substantial doubt about its ability to continue as a going concern.
• Regulatory Changes (Federal THC Limit): New federal legislation, effective November 13, 2026, will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container, which could have a material adverse impact on the company's business, as products with less than this amount currently represent a small portion of the market.
• Regulatory Changes (State Level): Differing and evolving state regulations, such as California's emergency order banning certain hemp products with detectable THC (extended to March 25, 2026), have negatively impacted operating results and are expected to continue to do so.
• Intense Competition: The market is fragmented and highly competitive due to a lack of clear regulatory framework, leading to competition from both licensed and illicit operators.
• Liquidity Dependence: The company is dependent on additional investment capital to fund operations and growth initiatives, with no assurance that such capital will be available on favorable terms or at all.
• Supply Chain & Manufacturing Constraints: Temporary out-of-stock situations for key products are expected in Q4 2025 and potentially early 2026 due to manufacturing constraints.
• Tariffs and Trade Policies: Increased tariffs on imports from China, where certain components are sourced, could force price increases or operational changes, harming revenue or operating results.
• Economic Conditions: Global economic conditions, rising inflation, and high interest rates may adversely impact the business, financial position, and cash flow.
• Legal Dispute with Former Counsel: Ongoing arbitration with former legal counsel Procopio seeking damages for alleged reliance on incorrect tax advice.
• Product Labeling Class Action: A putative class action lawsuit regarding product labeling remains stayed, with the FDA not intending to pursue rulemaking, creating ongoing uncertainty.

Future Outlook

Management anticipates continued dependence on additional investment capital to fund operations and growth initiatives. The company plans to raise funds through capital markets, debt, and/or lines of credit. Strategic cost reductions, including employee headcount and delaying drug development expenses, are ongoing. The company is assessing the potential material adverse impact of new federal legislation, effective November 13, 2026, which will prohibit the sale of hemp-derived products containing more than 0.4 milligrams of total THC per container. Manufacturing constraints are expected to cause temporary out-of-stock situations for key products in Q4 2025 and early 2026, with supply expected to normalize in 2026.

Management Comments

• We intend to continue to innovate new products, build brand awareness, and make significant investments in our business strategy by introducing new products into the markets in which we operate, adopt quality assurance protocols and procedures, build our market presence, and undertake further research and development.
• We intend to make additional acquisitions to further diversify our product offerings.
• Management implemented, and continues to make and implement, strategic cost reductions, including reductions in employee headcount, vendor spending, and the delaying of certain expenses related to our drug development activities.
• To the extent that we feel it is necessary and in the best interest of the Company and our shareholders, we may also take further actions that alter our operations in order to ensure the success of our business.
• We are working closely to resolve these [manufacturing] issues and expect supply to normalize in 2026.

Industry Context

The hemp-derived product market remains fragmented and highly competitive, largely due to the absence of a clear federal regulatory framework and a patchwork of evolving state regulations. This environment allows for intense competition from both licensed and illicit market operators. The recent federal legislation imposing a 0.4mg total THC limit per container, effective November 2026, represents a significant shift that could reshape the industry, potentially disadvantaging companies like CV Sciences whose current product portfolio may not align with the new standard. The company's strategy of new product innovation, brand building, and potential acquisitions is a common response to such a dynamic and competitive landscape.

Corporate Governance

Legal Proceedings

• Ruth Complaint (Shareholder Derivative Suit): A settlement in principle was reached in January 2022, involving corporate governance reforms. The court granted preliminary approval on February 7, 2023, and subsequently granted plaintiff's motion for attorney's fees and expenses of approximately $250,000 on May 23, 2023. A stipulation for payment over approximately eighteen months, subject to a confession of judgment, was executed on May 1, 2024.
• Colette Complaint (Putative Class Action Product Labeling): This lawsuit, alleging violations of the Food, Drug, and Cosmetic Act of 1938 regarding product labeling, remains stayed. The court's order stated the stay would remain until the FDA completed rulemaking on CBD ingestible products. Despite the FDA announcing on January 26, 2023, that it does not intend to pursue such rulemaking, the case remains stayed.
• Arbitration with Procopio (Legal Counsel Dispute): Initiated on February 12, 2025, asserting claims against former legal counsel Procopio for damages resulting from reliance on alleged incorrect tax advice concerning former CEO Mona's RSU settlement. The hearing is scheduled to begin on May 18, 2026.

Related Party Transactions

• The company derecognized a $0.5 million contingent liability for employer and employee Medicare FICA taxes related to former CEO Mona's RSU settlement, due to the expiration of the statute of limitations on April 15, 2025. This follows a previous derecognition of $6.2 million for income taxes in Q1 2023 related to the same matter.
• The company is engaged in an arbitration with its former legal counsel, Procopio, regarding legal advice provided concerning Mona's RSU tax withholding.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future capital raises, uncertainty regarding the company's going concern ability, and potential adverse impacts from new federal THC regulations. The purported termination of the Extract Labs acquisition also adds uncertainty.
• Employees: Subject to strategic cost reductions, including potential reductions in headcount.
• Customers: May experience temporary out-of-stock issues for key products in Q4 2025 and early 2026 due to manufacturing constraints. Future product availability and offerings will be impacted by new federal THC regulations.
• Suppliers: May be affected by strategic cost reductions and changes in product formulations due to regulatory shifts.
• Creditors: The company's dependence on additional capital and 'going concern' doubt indicates elevated risk. Existing debt is secured by all company assets.

Next Steps

• Assess and potentially modify product formulations, labeling, and compliance measures in response to new federal THC legislation by November 13, 2026.
• Continue strategic cost reductions, including employee headcount and vendor spending.
• Pursue capital-raising efforts through capital markets, debt issuance, and/or securing lines of credit.
• Resolve manufacturing constraints to normalize supply in 2026.
• Evaluate options related to the purported termination of the Extract Labs acquisition agreement.
• Proceed with the arbitration hearing against Procopio, scheduled for May 18, 2026.
• Continue to monitor and respond to evolving state and federal regulations regarding CBD and hemp-derived products.

Key Dates

Recommendation

CV Sciences faces severe headwinds that collectively present a 'strong sell' recommendation. The company explicitly states 'substantial doubt about the Company's ability to continue as a going concern,' a critical red flag for investors. While net losses have narrowed, sales are declining significantly due to out-of-stock issues and restrictive state regulations. The most impactful factor is the impending federal legislation, effective November 2026, which will prohibit the sale of hemp-derived products with over 0.4mg total THC. This directly threatens the company's core business, as products compliant with this new limit currently represent only a 'small portion' of their market. This regulatory change, combined with ongoing liquidity challenges, dependence on further capital raises, and manufacturing constraints, creates an extremely high-risk profile. The recent $300,000 capital raise is insufficient to address the fundamental issues. The legal dispute with former counsel and the stalled class action lawsuit add further uncertainty and potential liabilities. Given the existential threat from regulation and persistent financial fragility, the stock carries significant downside risk.

Keywords

CV Sciences, Hemp-derived products, CBD, Cannabidiol, Nutraceuticals, Plant-based foods, SEC 10-Q, Financial results, Regulatory risk, Going concern, THC limits, Capital raise, Liquidity, Operating loss, Gross margin, Stock options, Legal proceedings, Supply chain, Tariffs